Item no. |
HY-10207-100mg |
Manufacturer |
MedChem Express
|
CASRN |
692737-80-7 |
Amount |
100 mg |
Quantity options |
100 mg
10mM/1mL
10 mg
200 mg
500 mg
50 mg
5 mg
|
Category |
|
Type |
Inhibitors |
Specific against |
other |
Purity |
99.62 |
Formula |
C24H27FN6O4 |
Citations |
[1]Trudel S, et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood. 2005, 105(7), 2941-2948.<br>[2]Huynh H, et al. Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma. J Hepatol. 2012, 56(3), 595-601. |
Smiles |
O=C(N1)C(C(NC2=C3)=NC2=CC=C3N4CCN(C)CC4)=C(N)C5=C1C=CC=C5F.O=C(O)C(C)O |
ECLASS 10.1 |
32160490 |
ECLASS 11.0 |
32160490 |
UNSPSC |
12000000 |
Alias |
CHIR-258 lactate; TKI-258 lactate |
Available |
|
Product Description |
Dovitinib lactate (TKI258 lactate) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/3, VEGFR1/2/3 and PDGFRα/β, respectively[1]. |
StorageTemperature |
4°C (Powder, sealed storage, away from moisture) |
Shipping |
Room Temperature |
Manufacturers Applications |
Cancer-Kinase/protease |
MolecularWeight |
482.51 |
Clinical_Information |
Phase 3 |
Manufacturers Research Area |
Cancer |
Solubility |
DMSO : 25 mg/mL (ultrasonic) |
Manufacturers Target |
c-Kit; FGFR; FLT3; PDGFR; VEGFR |
Isoform |
FGFR1; FGFR3; PDGFRα; PDGFRβ; VEGFR1/Flt-1; VEGFR2/KDR/Flk-1; VEGFR3/Flt-4 |
Pathway |
Protein Tyrosine Kinase/RTK |
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.